Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peripheral T-cell receptor repertoire and extracellular vesicle biomarkers in HCC patients treated with tremelimumab plus durvalumab
jRCT1061240056Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of tremelimumab and durvalumab in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Primary endpoint: Primary: Association of early TCR repertoire changes with potential long-term survival. Started Sep 2024; status: recruiting.
02
Drugs
tremelimumabdurvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT1061240056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061240056.